Soft tissue sarcomas (STS) are highly malignant cancers with mesenchymal origin. In many instances, clinical outcome is poor due to high rates of local recurrence and metastasis.
To overcome these limitations, we evaluated the expression patterns of intratumoral PD-L1, the amount of TILs and their PD-1 expression status, as well as associations with clinicopathological parameters in a large and comprehensive cohort of 274 samples comprising more than six STS subtypes.
We found that nearly all STS subtypes showed partial PD-L1 expression, albeit with a broad range of PD-L1 positivity across subtypes (50% angiosarcomas, 23% UPS, 13% leiomyosarcomas, 12% dedifferentiated liposarcomas, 3% synovial sarcomas, 0 MPNST, and 18% mixed sarcomas). Co-expression and correlation analyses uncovered that expression of PD-L1 was associated with more PD-1 positive TILs (P < 0.001), higher tumor grading (P = 0.022) and worse patients' 5-year overall survival (P = 0.016).
In sum, the substantial portion of STS showing PD-L1 expression, the simultaneous presence of PD-1 positive TILs, and the association of PD-L1 with unfavorable clinical outcome provide a rationale for immune checkpoint inhibition in patients with PD-L1-positive STS.
INTRODUCTION
Soft tissue sarcomas (STS) are heterogeneous and highly malignant tumors originating from the mesenchymal lineage 1 with more than 50 subtypes described to date 2 . Current therapy regimens for STS are limited mainly to surgery and radiation 3 . Benefits of neoadjuvant and adjuvant radiochemotherapy are still under debate 3, 4 . In addition, established therapies appear not fully sufficient for long-time tumor control as many patients develop local relapse (up to 45%) and/or distant metastases (30%) 1, 5, 6 , leading to fatal outcome.
Unfortunately, STS patients barely benefited from new and more sophisticated anti-cancer treatments like kinase inhibitors 3 , and innovative and more effective therapeutic alternatives are lacking, possibly due to the rarity and diversity of STS.
In the past two decades, immune checkpoint inhibitors revolutionized anti-cancer therapies.
Immune checkpoint inhibitors like Nivolumab interfere with an immunosuppressive mechanism by which cancer cells attenuate the anti-cancer activity of the patient's immune system 7 . Specifically, several cancer cells hijack a regulatory mechanism of the immune system by expression of programmed death receptor ligand 1 (PD-L1, B7-H1, CD274) 8 . PD-L1 is normally expressed on antigen presenting cells and binds to the programmed death receptor 1 (PD-1) on activated T cells, B cells, and macrophages, thereby blocking their activity and the recruitment of further immune cells 9 . In melanoma and urothelial carcinoma with PD-L1 expression, inhibition of this immune checkpoint enhances anti-tumor immune activity resulting in significantly improved clinical outcome 10, 11 .
However, to date there is not any extensive study on STS that has comprehensively investigated whether PD-L1 expression is a common feature in STS, if PD-L1-positive STS exhibit tumor infiltrating lymphocytes (TILs), and whether those TILs are positive for PD-1 as a prerequisite of PD-L1 and PD-1 interaction 9,12-14 .
In the present study, we analyzed these aspects in a large tissue microarray (TMA) comprising 225 STS samples of six distinct subtypes and 22 additional samples of various other STS subtypes. Our results show that a substantial proportion of STS is positive for PD-L1 and that PD-L1 expression is associated with PD-1 positive TILs, and poor patient outcome, providing a rationale for immune checkpoint inhibition in these STS patients.
MATERIALS AND METHODS

Patient cohort
Formalin fixed paraffin-embedded tumor material from STS patients was retrieved from the Table 1) .
Assembly of TMAs
For TMA assembly, representative tumor areas were marked on hematoxylin and eosin (H&E) stained slides of the selected paraffin blocks of each patient, and two cores with 0.6 mm diameter were taken from each sample. Samples from tonsils were added as positive controls. 
Statistical analyses
For statistical analyses PD-L1 expression was classified as negative (0) were considered statistically significant.
RESULTS
PD-L1 is expressed in several STS subtypes
To test whether PD-L1 expression at protein level is a common feature of STS, we stained
TMAs with 247 STS samples represented as duplicates by immunohistochemistry ( Table 1) using an automated immunostainer and a well-established routine antibody for PD-L1, and considered all samples with >1% membranous staining as PD-L1 positive, the remaining as negative (Figure 1) . The fraction of positive samples comprised 50% of angiosarcomas, 23%
of undifferentiated pleomorphic sarcomas (UPS), 13% of leiomyosarcomas, 12% of dedifferentiated liposarcomas, 4% of synovial sarcomas, 0 MPNST, and 22% of mixed sarcomas ( Table 2) . On average, 16% of the entire cohort exhibited PD-L1 expression.
Hence, a substantial fraction of STS tumors expresses PD-L1 at protein level, albeit with variable proportions depending on the STS subtype.
PD-L1 expression in STS correlates with PD-1 positive TILs
Besides PD-L1 expression, another prerequisite for effective immune checkpoint inhibition in cancer is an actual interaction of PD-L1 with its receptor. Accordingly, we scored the total number of TILs and TILs positive for PD-1 for all samples tested for PD-L1 positivity considering samples with counts of ≥4 lymphocytes per HPF as positive (Figure 2) . positive samples the fractions for TIL and PD-1 positivity were 87.2% and 62.9% (Table 3) .
In fact, for all tested STS subtypes with ≥6 PD-L1 positive samples, the fraction of PD-1 positivity was higher in the PD-L1 expressing samples than in those negative for PD-L1.
Consistently, PD-L1 expression and PD-1 positivity were highly significantly correlated (P < 0.001, Table 3 ).
Taken together, these results provide evidence that PD-L1 positive STS are enriched for PD-1 positivity, pointing to an actual interaction of PD-L1 and PD-1 positive TILs in STS, which is a prerequisite for patients' eligibility for immune checkpoint inhibitor therapy.
PD-L1 expression is associated with clinical outcome in STS
To test whether the PD-L1 status is associated with clinicopathological parameters, we correlated the PD-L1 scoring results obtained from assessors blinded to the clinical data with the most important prognostic parameters for STS patients.
While PD-L1 expression did not correlate with age and tumor size in any tested STS subtype, it was significantly enriched in males (P = 0.009) and significantly associated with the prognostically favorable tumor localization in the extremities (P = 0.006). In contrast, PD-L1 expression was significantly associated with the prognostically unfavorable parameters of high grading (P = 0.022), metastasis at diagnosis (P = 0.021), and higher rates of proliferating cells
(assessed by percentage of Ki-67 positive tumor cells, P = 0.046) ( Table 4 ). In accordance, intratumoral PD-L1 expression was associated with a significantly worse 5-year overall survival (37% vs. 58% 5-year overall survival probability, P = 0.016) (Table 4, Figure 3) . In synopsis, these data indicate that PD-L1 expression is clinically relevant in STS patients.
DISCUSSION
Immune checkpoint inhibitors interfering with the interaction of tumoral PD-L1 and PD-1 on
TILs show promising results as anti-cancer drugs in recent studies, e.g. for melanoma and bladder carcinoma 10, 11 . So far, the applicability of these inhibitors for STS patients has not been studied extensively 15 .
Since any targeted therapy is prone to fail in the absence of the target 16 , we first assessed the PD-L1 expression in STS at protein level. To this end, we compiled a cohort of 247 tumor samples from STS patients with matched and well-curated clinical data, including median follow-up of 3 years. The cohort comprised six distinct and representative STS subtypes, including the three most common subtypes in adults (UPS, liposarcoma, leiomyosarcoma) with ≥47 samples, and additional 22 mixed STS cases. Thus, to the best of our knowledge, our analyses were based on the largest and most comprehensive STS cohort to date 13, 17 .
For MPNST not any sample was scored as positive for PD-L1, for angiosarcomas 50%, which indicates a strong variability of PD-L1 expression depending on the STS subtype. However, it should be noted that for both subtypes showing extreme variability of PD-L1 only a limited number of samples (11 and 6, respectively) were available.
Interestingly, 23% of UPS cases (19/83) were positive for PD-L1, while only 13% of leiomyosarcomas (6/47) and 12% of dedifferentiated liposarcomas (6/49) showed PD-L1
expression. This is in line with prior studies in other cancers correlating mutational burden, which is much higher in UPS compared to leiomyosarcoma and liposarcoma 18 , with enhanced neoantigen presentation 19, 20 . Hence, immune checkpoint inhibition may be in particular effective in UPS.
As PD-L1 acts as ligand of PD-1, we next investigated the positivity for PD-1 expressing TILs in the same patients' specimens tested for PD-L1 positivity. Across all STS subtypes with ≥6 samples, the rate of PD-1 positive samples in PD-L1 expressing ones was higher than in the negative ones. These results are supported by previous studies in smaller STS cohorts or single STS subtypes demonstrating a PD-L1 and PD-1 interaction 13, 14, 17, 21 , which collectively provide a strong rationale that PD-L1 positive patients are eligible for immune checkpoint inhibitor therapy. Furthermore, our findings support the hypothesis that cancer cells can dynamically increase PD-L1 expression to protect themselves in settings of increased numbers of TILs 12 .
Besides the role of PD-L1 as a biomarker to guide clinical decisions on the implementation of immunotherapy, we evaluated its prognostic relevance. In our large STS cohort we found that intratumoral PD-L1 expression was associated with significantly worse 5-year overall survival Red: PD-L1 positive; grey: PD-L1 negative; significance was assessed by log-rank test. 
